Premium
Thalidomide in angiodysplasia‐related bleeding
Author(s) -
Boey J. P.,
Hahn U.,
Sagheer S.,
McRae S. J.
Publication year - 2015
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12850
Subject(s) - medicine , angiodysplasia , thalidomide , gastrointestinal bleeding , refractory (planetary science) , intervention (counseling) , surgery , intensive care medicine , physics , astrobiology , multiple myeloma , psychiatry
Gastrointestinal haemorrhage from angiodysplastic lesions is not only difficult to identify, but often refractory to endoscopic intervention. Patients often require substantial transfusion support. Thalidomide has emerged as a promising medical strategy in angiodysplasia‐related bleeding. We present our experience and report the findings from a review of the literature. Despite its side‐effect profile, thalidomide remains the therapeutic modality with the best evidence in this difficult clinical scenario.